StockMacro
Menu

AstraZeneca

$174.35 -6.9% in 6 monthsMarket cap $270.4B

AZN on XNYS, AstraZeneca PLC, job postings

Measures activity, not value. Not investment advice.

News volume hit 10.5 times its usual week, 58 articles, but the stock is down 1.7% in a year.

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 31 Dec 2025

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Employees
96,100
Website
astrazeneca.com
Listed
NYSE, US
Fundamentals, 12 months to 31 Dec 2025
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $58.7B $54.1B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +8.6%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $10.2B $7.0B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $6.54 $4.50
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 81.9% 81.1%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 23.4% 18.5%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 17.4% 13.0%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 22.9%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $11.8B $9.9B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $5.7B $5.5B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. –
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 26.4
P/SPrice to sales: market cap divided by revenue of the last 12 months. 4.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. –
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 5.6

Latest = 12 months to 31 Dec 2025; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$3K

bought $3K, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-2.9%

1,433 13F filers vs 1,476

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

–

3.0M shares sold short (30 Oct 2026); no share count in the company's filings in our data

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.0

3.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-7.6%

3.3M shares sold short in the report before, 3.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

35%

35% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

840

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$5.9M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

66

66 articles in the last 7 days; its usual week has 6 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

66 articles in the last 7 days; its usual week has 6.

Price $174.35 on 20 Nov 2026, -1.7% over 12 months (12-month range $155.62 to $209.48)

  • Sharp change
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $2.2M in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 24 published in the last 12 months (none in the 12 months before).
Institutional holders (13F filers). 1,433 13F filers reported holding it in the latest 13F quarter, +16% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.
Lobbying spend. Lobbying spend: $5.9M published in the last 12 months, +3.5% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: revenue per quarter, capital spending per quarter, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
16 Sep 2026Lobbying filingnew lobbying registration (THOLOS GOVERNMENT RELATIONS)
11 Aug 2026Sharp changeWikipedia attention spike: wikipedia attention spike, 6,503 vs usual 3,675 (2026-08-03..2026-08-09); 1.2x the same week a year earlier
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 253 vs usual 104.50 (2026-03-31); 2.2x the same period a year earlier
14 Oct 2025Sharp changeWikipedia attention spike: wikipedia attention spike, 9,799 vs usual 5,013 (2025-10-06..2025-10-12); 1.9x the same week a year earlier
20 May 2025Sharp changeWikipedia attention spike: wikipedia attention spike, 13K vs usual 5,027.50 (2025-05-12..2025-05-18); 1.7x the same week a year earlier
18 Mar 2025Sharp changeShort interest spike: short interest spike, 17.0M vs usual 8.0M (2025-02-28); 1.8x the same period a year earlier
4 Mar 2025Sharp changeShort interest spike: short interest spike, 15.5M vs usual 8.0M (2025-02-14); 1.7x the same period a year earlier
18 Feb 2025Sharp changeShort interest spike: short interest spike, 16.9M vs usual 7.8M (2025-01-31); 4.1x the same period a year earlier
28 Jan 2025Sharp changeShort interest spike: short interest spike, 15.1M vs usual 7.7M (2025-01-15); 2.6x the same period a year earlier
7 May 2024Sharp changeWikipedia attention spike: wikipedia attention spike, 30K vs usual 5,736.50 (2024-04-29..2024-05-05); 5.9x the same week a year earlier
9 Jan 2024Lobbying filinglobbying engagement terminated (SQUIRE PATTON BOGGS)
18 Jul 2023Lobbying filinglobbying engagement terminated (TODD STRATEGY GROUP)
19 Jan 2023Lobbying filinglobbying engagement terminated (RAMPY NORTHRUP LLC)
18 Jan 2023Lobbying filinglobbying engagement terminated (PRIME POLICY GROUP)
6 Jul 2022Lobbying filingnew lobbying registration (SQUIRE PATTON BOGGS)
31 May 2022Sharp changeShort interest spike: short interest spike, 16.4M vs usual 7.7M (2022-05-13); 0.1x the same period a year earlier
20 Jan 2022Lobbying filinglobbying engagement terminated (PRIME POLICY GROUP)
20 Jan 2022Lobbying filingnew lobbying registration (PRIME POLICY GROUP)
Insider net buying (open market)
Month from 1 May 2026: -$2.2M published
Month from 1 Sep 2026: $3K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2026: 24 published
Institutional holders (13F filers)
31 Dec 2021 report: 832; public on 14 Feb 2022
31 Mar 2022 report: 909; public on 16 May 2022
30 Jun 2022 report: 944; public on 15 Aug 2022
30 Sep 2022 report: 880; public on 14 Nov 2022
31 Dec 2022 report: 966; public on 14 Feb 2023
31 Mar 2023 report: 967; public on 15 May 2023
30 Jun 2023 report: 999; public on 14 Aug 2023
30 Sep 2023 report: 973; public on 14 Nov 2023
31 Dec 2023 report: 1,031; public on 14 Feb 2024
31 Mar 2024 report: 1,067; public on 15 May 2024
30 Jun 2024 report: 1,150; public on 14 Aug 2024
30 Sep 2024 report: 1,157; public on 14 Nov 2024
31 Dec 2024 report: 1,160; public on 14 Feb 2025
31 Mar 2025 report: 1,191; public on 15 May 2025
30 Jun 2025 report: 1,168; public on 14 Aug 2025
30 Sep 2025 report: 1,234; public on 14 Nov 2025
31 Dec 2025 report: 1,334; public on 17 Feb 2026
31 Mar 2026 report: 1,350; public on 15 May 2026
30 Jun 2026 report: 1,476; public on 14 Aug 2026
30 Sep 2026 report: 1,433; public on 16 Nov 2026
Federal obligations
Month from 1 Jan 2022: -$287.1M published
Month from 1 Feb 2022: $18K published
Month from 1 Apr 2022: $6.9M published
Month from 1 May 2022: $855.0M published
Month from 1 Jun 2022: $0 published
Month from 1 Jul 2022: $1.1M published
Month from 1 Aug 2022: $2.2M published
Month from 1 Sep 2022: $29K published
Month from 1 Oct 2022: $68K published
Month from 1 Feb 2023: $19K published
Month from 1 Jun 2023: $0 published
Month from 1 Aug 2023: $20K published
Month from 1 Nov 2023: -$34K published
Month from 1 Feb 2024: $500 published
Lobbying spend
Quarter from 1 Jan 2022: $1.6M published
Quarter from 1 Apr 2022: $1.6M published
Quarter from 1 Jul 2022: $1.5M published
Quarter from 1 Oct 2022: $1.2M published
Quarter from 1 Jan 2023: $1.3M published
Quarter from 1 Apr 2023: $1.4M published
Quarter from 1 Jul 2023: $970K published
Quarter from 1 Oct 2023: $1.1M published
Quarter from 1 Jan 2024: $970K published
Quarter from 1 Apr 2024: $840K published
Quarter from 1 Jul 2024: $1.1M published
Quarter from 1 Oct 2024: $790K published
Quarter from 1 Jan 2025: $780K published
Quarter from 1 Apr 2025: $1.4M published
Quarter from 1 Jul 2025: $2.0M published
Quarter from 1 Oct 2025: $1.5M published
Quarter from 1 Jan 2026: $840K published
Quarter from 1 Apr 2026: $2.4M published
Quarter from 1 Jul 2026: $1.7M published
Quarter from 1 Oct 2026: $970K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $3K (11 Sep 2026), too little history to compare.
  • Wikipedia attention spike: drew 6,503 Wikipedia page views in the week of 3 Aug 2026, 1.2× the same week last year Public on 11 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $2.2M in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 24 published in the last 12 months (none in the 12 months before).

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 2 insider trades

Last 90 days: no sales; 1 purchase, $3K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
11 Sep 2026Mani SharmaSee RemarksBuy20$160.57$3KForm 4
22 May 2026Mani SharmaSee RemarksSell11,893$185.78$2.2MForm 4

1,433 institutions reported shares at the end of Q3 2026; 131 opened a position, 168 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Investor Ab51.6M$8.3BNo change
Vanguard Capital Management LLC45.7M$7.4B+271K+0.6%
Capital World Investors31.1M$5.1B+1.0M+3.4%
Wellington Management Group LLP30.8M$5.0B+2.3M+8.1%
FMR LLC (Fidelity)29.4M$4.8B+488K+1.7%
Legal & General Group Plc26.2M$4.3B+434K+1.7%
T. Rowe Price Associates Inc19.3M+2.7M+16%
VANGUARD ASSET MANAGEMENT, Ltd19.1M$3.1B+404K+2.2%
Franklin Templeton Inc19.1M$3.6B+2.5M+15%
JPMorgan Chase & Co18.4M$3.0B-777K-4.0%

Federal contracts

All 17 federal contracts

No new award in 12 months; the latest was signed 13 Aug 2021. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
13 Aug 2021Department of Health and Human ServicesNational Institutes of Health$5.3MA NOVEL AND HIGHLY SELECTIVE OREXIN 1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF PATIENTS WITH OPIOID USE DISORDER. - PROJECT SUMMARY OPIOID USE DISORDER (OUD) IS A PUBLIC HEALTH CRISIS. CURRENT TREATMENTS SHOW LIMITED EFFICACY AND FAIL TO PREVENT RELAPSE TO DRUG USE DURING ATTEMPTED ABSTINENCE AND DRUG-OVERDOSE ARE ALL TOO FREQUENT. IN COLLABORATION WITH EOLAS THERAPEUTICS AND THE NIH BLUEPRINT NEUROTHERAPEUTICS NETWORK, ASTRAZENECA HAS DEVELOPED A POTENT AND SELECTIVE OX1 RECEPTOR ANTAGONIST (AZGrantUSAspending
28 Oct 2020Department of DefenseDepartment of the Army$0PRODUCTION OF COVID-19 AZD1222 VACCINE IN SUPPORT OF NATIONAL EMERGENCY RESPONSE TO CORONAVIRUS 2019 (COVID-19)USAspending
30 Sep 2020Department of DefenseDepartment of the Army$1.1BSARS-COV-2 THERAPEUTIC AZD7442USAspending
20 May 2020Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$125.6MISSUE ADVANCED AGREEMENT PRIOR TO AWARD OF AN OTHER TRANSACTION AGREEMENT (OTA)FOR THE COVID19 VACCINE DEVELOPMENT AND MANUFACTURINGUSAspending
22 Aug 2018Department of DefenseDepartment of the Army$937KA PHASE 1/2A CLINICAL TRIAL STUDY TO EVALUATE THE EFFICACY OF MEDI8852 IN THE TREATMENT OF INFLUENZA IN ADULTS CHALLENGED WITH A WILD-TYPE INFLUENZAGrantUSAspending
22 Sep 2016Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$1.8MASPR-16-05539USAspending
15 Sep 2015Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and ResponseIGF::OT::IGFUSAspending
12 Sep 2013Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$5.6MASPR-13-10103USAspending

840 open postings; careers site tracked since 21 Nov 2026. Most in Sales & business development 18%, Marketing & communications 10%, Research & science 7%, Legal, policy & compliance 6%.

PostedJobLocation
21 Nov 2026Medical Science Liaison - NeurologyBogotá, , Colombia
21 Nov 2026Site Lead, Business Excellence & TransformationBlanchardstown Road North, Dublin, Ireland
20 Nov 2026Director, Process Lead - Materials Planning and SupplySupply chain & procurementGaithersburg, Maryland, United States of America
20 Nov 2026Director, Process Lead - Integrated Planning and Capacity ManagementProcess engineering (semiconductor / materials)Gaithersburg, Maryland, United States of America
20 Nov 2026Associate Director, Real World Data ScienceData & analyticsMississauga, Ontario, Canada
20 Nov 2026Associate Director, Planning Data ManagerGaithersburg, Maryland, United States of America
20 Nov 2026Senior Director, Planning Center of Excellence (CoE) LeadGaithersburg, Maryland, United States of America
20 Nov 2026Associate Director - External QualityTest, quality & reliabilityGaithersburg, Maryland, United States of America

Reported lobbying spend: $970K in Q3 2026, $1.7M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
3 Aug 2026NewTholos Government Relationsfor Astrazeneca Pharmaceuticals LPIssues related to pharmaceuticals, intellectual property, and tradePharmacy, Copyright/patents, TradeFiling
1 Jan 2025EndedPrime Policy Groupfor Astrazeneca Pharmaceuticals LPNot statedFiling
17 Nov 2023EndedSquire Patton Boggsfor Astrazeneca Uk Ltd.Not statedFiling
31 Mar 2023EndedTodd Strategy Groupfor Astrazeneca Pharmaceuticals LPDrug Pricing. General issues related to rare disease and orphan drugs. General issues related to diagnostics for patients with rare diseases. Items related to the Administrations Cancer Moonshot. Prescription Drug User Fee Act (PDUFA).; General issues related to patient access to rare disease therapies, Part B and Part D drugs. Issues related to home infusion for Part B patients. Issues related to home infusion for Part B patients.; Issues related to the 340B drug discount program.Pharmacy, Health issues, Medicare/MedicaidFiling
31 Dec 2022EndedRampy Northrup LLCfor Astrazeneca Pharmaceuticals LPProvide legislative and regulatory advice related to vaccine development, drug pricing, the 340B Drug Pricing Program, PDUFA Reauthorization, and clinical trial diversity; H.R.6000, Cures 2.0 Act; H.R.5585, Advanced Research Project Agency-Health Act; H.R.5030/S.2706, DIVERSE Trials Act; H.R.7667, FPharmacyFiling
23 May 2022NewSquire Patton Boggsfor Astrazeneca Uk Ltd.Educating and advocating on issues related to AstraZenecas efforts to substitute a non-global warming gas as the propellant in its metered dose inhalers.EnvironmentFiling
1 Jan 2022NewPrime Policy Groupfor Astrazeneca Pharmaceuticals LPCOVID-19 vaccine and therapy development and deploymentPharmacyFiling
31 Dec 2021EndedPrime Policy Groupfor Burson Cohn & Wolfe On Behalf Of Astrazeneca Pharmaceuticals LPCOVID-19 vaccine development, manufacturing, and distributionHealth issuesFiling
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

23 Mar 2021confirmed

Confirmed across sources Attention and Short interest and volume

AstraZeneca (AZN): drew 222K Wikipedia page views in the week of 15 Mar 2021, 38× the same week last year, while it had 135.1M shares sold short in the 15 Jun 2021 report, 47× the same report last year. Two unrelated kinds of activity within 133 days.

  • Short interest and volume: Short interest spike, became public on 25 Feb 2021
  • Short interest and volume: Short interest spike, became public on 10 Mar 2021
  • Attention: Wikipedia attention spike, became public on 23 Mar 2021
  • Short interest and volume: Short interest spike, became public on 25 Mar 2021
  • Short interest and volume: Short interest spike, became public on 13 Apr 2021
  • Short interest and volume: Short interest spike, became public on 27 Apr 2021
  • Short interest and volume: Short interest spike, became public on 12 May 2021
  • Short interest and volume: Short interest spike, became public on 26 May 2021
  • Short interest and volume: Short interest spike, became public on 10 Jun 2021
  • Short interest and volume: Short interest spike, became public on 26 Jun 2021
  • Short interest and volume: Short interest spike, became public on 13 Jul 2021
2020-09-14: 15K2020-09-21: 13K2020-09-28: 9,9872020-10-05: 10K2020-10-12: 12K2020-10-19: 17K2020-10-26: 16K2020-11-02: 11K2020-11-09: 27K2020-11-16: 35K2020-11-23: 87K2020-11-30: 28K2020-12-07: 34K2020-12-14: 27K2020-12-21: 26K2020-12-28: 85K2021-01-04: 49K2021-01-11: 38K2021-01-18: 38K2021-01-25: 154K2021-02-01: 51K2021-02-08: 38K2021-02-15: 35K2021-02-22: 49K2021-03-01: 62K2021-03-08: 98K2021-03-15: 222K
The week of 15 Mar 2021 against the 26 weeks before it. this weekearliernormal: 34K
See the evidence (11 changes)

Short interest and volume: Short interest spike became public on 25 Feb 2021

AstraZeneca had 77.9M shares sold short in the 12 Feb 2021 report, 9.9× the same report last year.

This period
77.9M (the 12 Feb 2021 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+31.6
Same report last year
7.8M
History used
1,141 days
2020-02-14: 7.8M2020-02-28: 9.0M2020-03-13: 7.2M2020-03-31: 4.6M2020-04-15: 4.1M2020-04-30: 3.6M2020-05-15: 3.6M2020-05-29: 3.2M2020-06-15: 2.9M2020-06-30: 1.9M2020-07-15: 1.2M2020-07-31: 6.9M2020-08-14: 6.6M2020-08-31: 4.1M2020-09-15: 4.3M2020-09-30: 5.1M2020-10-15: 5.0M2020-10-30: 6.0M2020-11-13: 6.3M2020-11-30: 4.4M2020-12-15: 3.5M2020-12-31: 33.5M2021-01-15: 49.9M2021-01-29: 65.9M2021-02-12: 77.9M
the 12 Feb 2021 report24 earlier reportsnormal: 4.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Mar 2021

AstraZeneca had 86.3M shares sold short in the 26 Feb 2021 report, 9.6× the same report last year.

This period
86.3M (the 26 Feb 2021 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+35.2
Same report last year
9.0M
History used
1,155 days
2020-02-28: 9.0M2020-03-13: 7.2M2020-03-31: 4.6M2020-04-15: 4.1M2020-04-30: 3.6M2020-05-15: 3.6M2020-05-29: 3.2M2020-06-15: 2.9M2020-06-30: 1.9M2020-07-15: 1.2M2020-07-31: 6.9M2020-08-14: 6.6M2020-08-31: 4.1M2020-09-15: 4.3M2020-09-30: 5.1M2020-10-15: 5.0M2020-10-30: 6.0M2020-11-13: 6.3M2020-11-30: 4.4M2020-12-15: 3.5M2020-12-31: 33.5M2021-01-15: 49.9M2021-01-29: 65.9M2021-02-12: 77.9M2021-02-26: 86.3M
the 26 Feb 2021 report24 earlier reportsnormal: 4.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Attention: Wikipedia attention spike became public on 23 Mar 2021

AstraZeneca drew 222K Wikipedia page views in the week of 15 Mar 2021, 38× the same week last year.

This period
222K (the week of 15 Mar 2021)
Normal week (median of 26 earlier)
34K
Typical spread (median absolute deviation)
17K
How far from its usual level
+7.5
Same week last year
5,786
History used
810 days
2020-09-14: 15K2020-09-21: 13K2020-09-28: 9,9872020-10-05: 10K2020-10-12: 12K2020-10-19: 17K2020-10-26: 16K2020-11-02: 11K2020-11-09: 27K2020-11-16: 35K2020-11-23: 87K2020-11-30: 28K2020-12-07: 34K2020-12-14: 27K2020-12-21: 26K2020-12-28: 85K2021-01-04: 49K2021-01-11: 38K2021-01-18: 38K2021-01-25: 154K2021-02-01: 51K2021-02-08: 38K2021-02-15: 35K2021-02-22: 49K2021-03-01: 62K2021-03-08: 98K2021-03-15: 222K
the week of 15 Mar 202126 earlier weeksnormal: 34K

Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

Check it at the source: Wikimedia page view statistics.

Short interest and volume: Short interest spike became public on 25 Mar 2021

AstraZeneca had 94.9M shares sold short in the 15 Mar 2021 report, 13× the same report last year.

This period
94.9M (the 15 Mar 2021 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+39.0
Same report last year
7.2M
History used
1,172 days
2020-03-13: 7.2M2020-03-31: 4.6M2020-04-15: 4.1M2020-04-30: 3.6M2020-05-15: 3.6M2020-05-29: 3.2M2020-06-15: 2.9M2020-06-30: 1.9M2020-07-15: 1.2M2020-07-31: 6.9M2020-08-14: 6.6M2020-08-31: 4.1M2020-09-15: 4.3M2020-09-30: 5.1M2020-10-15: 5.0M2020-10-30: 6.0M2020-11-13: 6.3M2020-11-30: 4.4M2020-12-15: 3.5M2020-12-31: 33.5M2021-01-15: 49.9M2021-01-29: 65.9M2021-02-12: 77.9M2021-02-26: 86.3M2021-03-15: 94.9M
the 15 Mar 2021 report24 earlier reportsnormal: 4.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Apr 2021

AstraZeneca had 98.6M shares sold short in the 31 Mar 2021 report, 21× the same report last year.

This period
98.6M (the 31 Mar 2021 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+40.5
Same report last year
4.6M
History used
1,188 days
2020-03-31: 4.6M2020-04-15: 4.1M2020-04-30: 3.6M2020-05-15: 3.6M2020-05-29: 3.2M2020-06-15: 2.9M2020-06-30: 1.9M2020-07-15: 1.2M2020-07-31: 6.9M2020-08-14: 6.6M2020-08-31: 4.1M2020-09-15: 4.3M2020-09-30: 5.1M2020-10-15: 5.0M2020-10-30: 6.0M2020-11-13: 6.3M2020-11-30: 4.4M2020-12-15: 3.5M2020-12-31: 33.5M2021-01-15: 49.9M2021-01-29: 65.9M2021-02-12: 77.9M2021-02-26: 86.3M2021-03-15: 94.9M2021-03-31: 98.6M
the 31 Mar 2021 report24 earlier reportsnormal: 4.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Apr 2021

AstraZeneca had 107.3M shares sold short in the 15 Apr 2021 report, 26× the same report last year.

This period
107.3M (the 15 Apr 2021 report)
Normal report (median of 24 earlier)
5.1M
Typical spread (median absolute deviation)
1.7M
How far from its usual level
+40.5
Same report last year
4.1M
History used
1,203 days
2020-04-15: 4.1M2020-04-30: 3.6M2020-05-15: 3.6M2020-05-29: 3.2M2020-06-15: 2.9M2020-06-30: 1.9M2020-07-15: 1.2M2020-07-31: 6.9M2020-08-14: 6.6M2020-08-31: 4.1M2020-09-15: 4.3M2020-09-30: 5.1M2020-10-15: 5.0M2020-10-30: 6.0M2020-11-13: 6.3M2020-11-30: 4.4M2020-12-15: 3.5M2020-12-31: 33.5M2021-01-15: 49.9M2021-01-29: 65.9M2021-02-12: 77.9M2021-02-26: 86.3M2021-03-15: 94.9M2021-03-31: 98.6M2021-04-15: 107.3M
the 15 Apr 2021 report24 earlier reportsnormal: 5.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 May 2021

AstraZeneca had 118.1M shares sold short in the 30 Apr 2021 report, 33× the same report last year.

This period
118.1M (the 30 Apr 2021 report)
Normal report (median of 24 earlier)
5.6M
Typical spread (median absolute deviation)
2.3M
How far from its usual level
+33.6
Same report last year
3.6M
History used
1,218 days
2020-04-30: 3.6M2020-05-15: 3.6M2020-05-29: 3.2M2020-06-15: 2.9M2020-06-30: 1.9M2020-07-15: 1.2M2020-07-31: 6.9M2020-08-14: 6.6M2020-08-31: 4.1M2020-09-15: 4.3M2020-09-30: 5.1M2020-10-15: 5.0M2020-10-30: 6.0M2020-11-13: 6.3M2020-11-30: 4.4M2020-12-15: 3.5M2020-12-31: 33.5M2021-01-15: 49.9M2021-01-29: 65.9M2021-02-12: 77.9M2021-02-26: 86.3M2021-03-15: 94.9M2021-03-31: 98.6M2021-04-15: 107.3M2021-04-30: 118.1M
the 30 Apr 2021 report24 earlier reportsnormal: 5.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 May 2021

AstraZeneca had 125.4M shares sold short in the 14 May 2021 report, 35× the same report last year.

This period
125.4M (the 14 May 2021 report)
Normal report (median of 24 earlier)
6.2M
Typical spread (median absolute deviation)
3.1M
How far from its usual level
+25.5
Same report last year
3.6M
History used
1,232 days
2020-05-15: 3.6M2020-05-29: 3.2M2020-06-15: 2.9M2020-06-30: 1.9M2020-07-15: 1.2M2020-07-31: 6.9M2020-08-14: 6.6M2020-08-31: 4.1M2020-09-15: 4.3M2020-09-30: 5.1M2020-10-15: 5.0M2020-10-30: 6.0M2020-11-13: 6.3M2020-11-30: 4.4M2020-12-15: 3.5M2020-12-31: 33.5M2021-01-15: 49.9M2021-01-29: 65.9M2021-02-12: 77.9M2021-02-26: 86.3M2021-03-15: 94.9M2021-03-31: 98.6M2021-04-15: 107.3M2021-04-30: 118.1M2021-05-14: 125.4M
the 14 May 2021 report24 earlier reportsnormal: 6.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Jun 2021

AstraZeneca had 132.1M shares sold short in the 28 May 2021 report, 42× the same report last year.

This period
132.1M (the 28 May 2021 report)
Normal report (median of 24 earlier)
6.4M
Typical spread (median absolute deviation)
4.0M
How far from its usual level
+21.0
Same report last year
3.2M
History used
1,246 days
2020-05-29: 3.2M2020-06-15: 2.9M2020-06-30: 1.9M2020-07-15: 1.2M2020-07-31: 6.9M2020-08-14: 6.6M2020-08-31: 4.1M2020-09-15: 4.3M2020-09-30: 5.1M2020-10-15: 5.0M2020-10-30: 6.0M2020-11-13: 6.3M2020-11-30: 4.4M2020-12-15: 3.5M2020-12-31: 33.5M2021-01-15: 49.9M2021-01-29: 65.9M2021-02-12: 77.9M2021-02-26: 86.3M2021-03-15: 94.9M2021-03-31: 98.6M2021-04-15: 107.3M2021-04-30: 118.1M2021-05-14: 125.4M2021-05-28: 132.1M
the 28 May 2021 report24 earlier reportsnormal: 6.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jun 2021

AstraZeneca had 135.1M shares sold short in the 15 Jun 2021 report, 47× the same report last year.

This period
135.1M (the 15 Jun 2021 report)
Normal report (median of 24 earlier)
6.7M
Typical spread (median absolute deviation)
5.1M
How far from its usual level
+16.8
Same report last year
2.9M
History used
1,264 days
2020-06-15: 2.9M2020-06-30: 1.9M2020-07-15: 1.2M2020-07-31: 6.9M2020-08-14: 6.6M2020-08-31: 4.1M2020-09-15: 4.3M2020-09-30: 5.1M2020-10-15: 5.0M2020-10-30: 6.0M2020-11-13: 6.3M2020-11-30: 4.4M2020-12-15: 3.5M2020-12-31: 33.5M2021-01-15: 49.9M2021-01-29: 65.9M2021-02-12: 77.9M2021-02-26: 86.3M2021-03-15: 94.9M2021-03-31: 98.6M2021-04-15: 107.3M2021-04-30: 118.1M2021-05-14: 125.4M2021-05-28: 132.1M2021-06-15: 135.1M
the 15 Jun 2021 report24 earlier reportsnormal: 6.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Jul 2021

AstraZeneca had 136.9M shares sold short in the 30 Jun 2021 report, 71× the same report last year.

This period
136.9M (the 30 Jun 2021 report)
Normal report (median of 24 earlier)
20.2M
Typical spread (median absolute deviation)
18.6M
How far from its usual level
+4.2
Same report last year
1.9M
History used
1,279 days
2020-06-30: 1.9M2020-07-15: 1.2M2020-07-31: 6.9M2020-08-14: 6.6M2020-08-31: 4.1M2020-09-15: 4.3M2020-09-30: 5.1M2020-10-15: 5.0M2020-10-30: 6.0M2020-11-13: 6.3M2020-11-30: 4.4M2020-12-15: 3.5M2020-12-31: 33.5M2021-01-15: 49.9M2021-01-29: 65.9M2021-02-12: 77.9M2021-02-26: 86.3M2021-03-15: 94.9M2021-03-31: 98.6M2021-04-15: 107.3M2021-04-30: 118.1M2021-05-14: 125.4M2021-05-28: 132.1M2021-06-15: 135.1M2021-06-30: 136.9M
the 30 Jun 2021 report24 earlier reportsnormal: 20.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

1 Dec 2020confirmed

Confirmed across sources Attention and Institutional holdings

AstraZeneca (AZN): saw 106 13F filers open a new position in the quarter ended 30 Sep 2020, 2.0× the same quarter last year, while it drew 87K Wikipedia page views in the week of 23 Nov 2020, 15× the same week last year. Two unrelated kinds of activity within 14 days.

  • Institutional holdings: Many funds opening a new position, became public on 16 Nov 2020
  • Attention: Wikipedia attention spike, became public on 1 Dec 2020
2018-09-30: 532018-12-31: 412019-03-31: 602019-06-30: 442019-09-30: 542019-12-31: 622020-03-31: 532020-06-30: 1012020-09-30: 106
The quarter ended 30 Sep 2020 against the 8 quarters before it. this quarterearliernormal: 53.5
See the evidence (2 changes)

Institutional holdings: Many funds opening a new position became public on 16 Nov 2020

AstraZeneca saw 106 13F filers open a new position in the quarter ended 30 Sep 2020, 2.0× the same quarter last year.

This period
106 (the quarter ended 30 Sep 2020)
Normal quarter (median of 8 earlier)
53.5
Typical spread (median absolute deviation)
7.5
How far from its usual level
+4.7
Same quarter last year
54
History used
2,557 days
2018-09-30: 532018-12-31: 412019-03-31: 602019-06-30: 442019-09-30: 542019-12-31: 622020-03-31: 532020-06-30: 1012020-09-30: 106
the quarter ended 30 Sep 20208 earlier quartersnormal: 53.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Attention: Wikipedia attention spike became public on 1 Dec 2020

AstraZeneca drew 87K Wikipedia page views in the week of 23 Nov 2020, 15× the same week last year.

This period
87K (the week of 23 Nov 2020)
Normal week (median of 26 earlier)
16K
Typical spread (median absolute deviation)
4,565
How far from its usual level
+10.5
Same week last year
5,731
History used
698 days
2020-05-25: 12K2020-06-01: 22K2020-06-08: 30K2020-06-15: 18K2020-06-22: 14K2020-06-29: 12K2020-07-06: 9,8002020-07-13: 23K2020-07-20: 57K2020-07-27: 16K2020-08-03: 12K2020-08-10: 18K2020-08-17: 27K2020-08-24: 19K2020-08-31: 15K2020-09-07: 45K2020-09-14: 15K2020-09-21: 13K2020-09-28: 9,9872020-10-05: 10K2020-10-12: 12K2020-10-19: 17K2020-10-26: 16K2020-11-02: 11K2020-11-09: 27K2020-11-16: 35K2020-11-23: 87K
the week of 23 Nov 202026 earlier weeksnormal: 16K

Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

Check it at the source: Wikimedia page view statistics.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

5 May 2020confirmed

Confirmed across sources Attention and Lobbying

AstraZeneca (AZN): reported $1.7M of lobbying spend for the quarter ended 31 Mar 2020, 1.4× the same quarter last year, while it drew 33K Wikipedia page views in the week of 27 Apr 2020, 7.6× the same week last year. Two unrelated kinds of activity within 14 days.

  • Lobbying: Lobbying spend jump, became public on 20 Apr 2020
  • Attention: Wikipedia attention spike, became public on 5 May 2020
2018-03-31: $760K2018-06-30: $620K2018-09-30: $780K2018-12-31: $970K2019-03-31: $1.2M2019-06-30: $960K2019-09-30: $550K2019-12-31: $610K2020-03-31: $1.7M
The quarter ended 31 Mar 2020 against the 8 quarters before it. this quarterearliernormal: $770K
See the evidence (2 changes)

Lobbying: Lobbying spend jump became public on 20 Apr 2020

AstraZeneca reported $1.7M of lobbying spend for the quarter ended 31 Mar 2020, 1.4× the same quarter last year.

This period
$1.7M (the quarter ended 31 Mar 2020)
Normal quarter (median of 8 earlier)
$770K
Typical spread (median absolute deviation)
$175K
How far from its usual level
+3.5
Same quarter last year
$1.2M
History used
3,288 days
2018-03-31: $760K2018-06-30: $620K2018-09-30: $780K2018-12-31: $970K2019-03-31: $1.2M2019-06-30: $960K2019-09-30: $550K2019-12-31: $610K2020-03-31: $1.7M
the quarter ended 31 Mar 20208 earlier quartersnormal: $770K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Attention: Wikipedia attention spike became public on 5 May 2020

AstraZeneca drew 33K Wikipedia page views in the week of 27 Apr 2020, 7.6× the same week last year.

This period
33K (the week of 27 Apr 2020)
Normal week (median of 26 earlier)
6,322
Typical spread (median absolute deviation)
802
How far from its usual level
+22.5
Same week last year
4,352
History used
488 days
2019-10-28: 5,1202019-11-04: 5,5122019-11-11: 5,2402019-11-18: 6,4462019-11-25: 5,7312019-12-02: 6,1192019-12-09: 5,5292019-12-16: 5,3182019-12-23: 4,1332019-12-30: 4,7332020-01-06: 5,6712020-01-13: 6,1982020-01-20: 6,8122020-01-27: 6,4782020-02-03: 7,0692020-02-10: 7,6192020-02-17: 6,8652020-02-24: 7,2672020-03-02: 6,7702020-03-09: 5,8572020-03-16: 5,7862020-03-23: 7,7712020-03-30: 8,9872020-04-06: 9,3172020-04-13: 11K2020-04-20: 7,8022020-04-27: 33K
the week of 27 Apr 202026 earlier weeksnormal: 6,322

Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

Check it at the source: Wikimedia page view statistics.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 10 Nov 2026Institutional holdings record

    Connor, Clark & Lunn Investment Management Ltd. opened a $285.0M position (2026Q3 13F)

  2. 6 Nov 2026Institutional holdings record

    LBP AM SA opened a $863.0M position (2026Q3 13F)

  3. 16 Sep 2026Lobbying record

    ASTRAZENECA PHARMACEUTICALS LP: new lobbying registration (THOLOS GOVERNMENT RELATIONS) (dated 3 Aug 2026)

  4. 12 Sep 2026Insiders record

    Sharma Mani (See Remarks) bought 20 shares of AZN ($3,248) (dated 11 Sep 2026)

  5. 14 Aug 2026Institutional holdings record

    Caisse de depot et placement du Quebec opened a $274.0M position (2026Q2 13F)

  6. 11 Aug 2026Attention change

    drew 6,503 Wikipedia page views in the week of 3 Aug 2026, 1.2× the same week last year.

    Same week last year: 5,403; its normal week is 3,675.

    See the evidence
    This period
    6,503 (the week of 3 Aug 2026)
    Normal week (median of 26 earlier)
    3,675
    Typical spread (median absolute deviation)
    324
    How far from its usual level
    +5.9
    Same week last year
    5,403
    History used
    2,777 days
    2026-02-02: 5,3872026-02-09: 4,7072026-02-16: 3,9432026-02-23: 4,4232026-03-02: 3,4912026-03-09: 3,5742026-03-16: 3,4692026-03-23: 3,6932026-03-30: 3,4842026-04-06: 3,8352026-04-13: 3,9992026-04-20: 4,0092026-04-27: 4,5062026-05-04: 3,6712026-05-11: 3,8442026-05-18: 3,8712026-05-25: 3,3512026-06-01: 4,0932026-06-08: 3,4502026-06-15: 2,9442026-06-22: 2,9162026-06-29: 3,0182026-07-06: 3,0662026-07-13: 3,1032026-07-20: 3,0122026-07-27: 3,6792026-08-03: 6,503
    the week of 3 Aug 202626 earlier weeksnormal: 3,675

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  7. 11 Aug 2026Institutional holdings record

    DIMENSIONAL FUND ADVISORS LP opened a $551.0M position (2026Q2 13F)

  8. 15 May 2026Institutional holdings change

    saw 253 13F filers open a new position in the quarter ended 31 Mar 2026, 2.2× the same quarter last year.

    Same quarter last year: 116; its normal quarter is 104.

    See the evidence
    This period
    253 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    104
    Typical spread (median absolute deviation)
    21.5
    How far from its usual level
    +4.7
    Same quarter last year
    116
    History used
    4,565 days
    2024-03-31: 932024-06-30: 1292024-09-30: 932024-12-31: 862025-03-31: 1162025-06-30: 772025-09-30: 1382025-12-31: 1632026-03-31: 253
    the quarter ended 31 Mar 20268 earlier quartersnormal: 104

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  9. 15 May 2026Institutional holdings record

    INVESTOR AB opened a $10.2B position (2026Q1 13F)

  10. 15 May 2026Institutional holdings record

    Zurcher Kantonalbank (Zurich Cantonalbank) opened a $386.0M position (2026Q1 13F)

  11. 15 May 2026Institutional holdings record

    DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main opened a $2.5B position (2026Q1 13F)

  12. 14 May 2026Institutional holdings record

    AVIVA PLC opened a $2.1B position (2026Q1 13F)

  13. 13 May 2026Institutional holdings record

    Public Sector Pension Investment Board opened a $415.0M position (2026Q1 13F)

  14. 13 May 2026Institutional holdings record

    M&G PLC opened a $817.0M position (2026Q1 13F)

  15. 13 May 2026Institutional holdings record

    Korea Investment CORP opened a $261.0M position (2026Q1 13F)

  16. 7 May 2026Institutional holdings record

    Swiss National Bank opened a $1.2B position (2026Q1 13F)

  17. 1 May 2026Institutional holdings record

    ROYAL LONDON ASSET MANAGEMENT LTD opened a $2.0B position (2026Q1 13F)

  18. 24 Apr 2026Institutional holdings record

    Ninety One UK Ltd opened a $397.0M position (2026Q1 13F)

  19. 23 Apr 2026Institutional holdings record

    Lansforsakringar Fondforvaltning AB (publ) opened a $474.0M position (2026Q1 13F)

  20. 22 Apr 2026Institutional holdings record

    Pictet Asset Management Holding SA opened a $675.0M position (2026Q1 13F)

  21. 17 Feb 2026Institutional holdings record

    HARRIS ASSOCIATES L P opened a $343.0M position (2025Q4 13F)

  22. 14 Oct 2025Attention change

    drew 9,799 Wikipedia page views in the week of 6 Oct 2025, 1.9× the same week last year.

    Same week last year: 5,280; its normal week is 5,013.

    See the evidence
    This period
    9,799 (the week of 6 Oct 2025)
    Normal week (median of 26 earlier)
    5,013
    Typical spread (median absolute deviation)
    536
    How far from its usual level
    +6.0
    Same week last year
    5,280
    History used
    2,476 days
    2025-04-07: 5,0462025-04-14: 4,4382025-04-21: 4,3002025-04-28: 4,4122025-05-05: 4,2632025-05-12: 13K2025-05-19: 6,8722025-05-26: 5,4532025-06-02: 5,1112025-06-09: 4,4812025-06-16: 4,5722025-06-23: 4,2462025-06-30: 5,5542025-07-07: 5,2072025-07-14: 4,2772025-07-21: 7,9592025-07-28: 5,4642025-08-04: 5,4032025-08-11: 4,9102025-08-18: 4,7122025-08-25: 4,4342025-09-01: 4,9802025-09-08: 5,5872025-09-15: 5,3042025-09-22: 4,9222025-09-29: 5,5712025-10-06: 9,799
    the week of 6 Oct 202526 earlier weeksnormal: 5,013

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  23. 20 May 2025Attention change

    drew 13K Wikipedia page views in the week of 12 May 2025, 1.7× the same week last year.

    Same week last year: 7,651; its normal week is 5,028.

    See the evidence
    This period
    13K (the week of 12 May 2025)
    Normal week (median of 26 earlier)
    5,028
    Typical spread (median absolute deviation)
    328
    How far from its usual level
    +15.2
    Same week last year
    7,651
    History used
    2,329 days
    2024-11-11: 6,0522024-11-18: 5,3872024-11-25: 5,1662024-12-02: 5,0372024-12-09: 4,8952024-12-16: 4,5942024-12-23: 3,7632024-12-30: 3,9722025-01-06: 5,1532025-01-13: 5,3012025-01-20: 5,2802025-01-27: 7,6202025-02-03: 5,7442025-02-10: 5,0182025-02-17: 5,0752025-02-24: 5,1312025-03-03: 4,7312025-03-10: 4,5232025-03-17: 5,1462025-03-24: 4,3202025-03-31: 4,8592025-04-07: 5,0462025-04-14: 4,4382025-04-21: 4,3002025-04-28: 4,4122025-05-05: 4,2632025-05-12: 13K
    the week of 12 May 202526 earlier weeksnormal: 5,028

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  24. 12 Mar 2025Short interest and volume change

    had 17.0M shares sold short in the 28 Feb 2025 report, 1.8× the same report last year.

    Same report last year: 9.3M; its normal report is 8.0M.

    See the evidence
    This period
    17.0M (the 28 Feb 2025 report)
    Normal report (median of 24 earlier)
    8.0M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +3.9
    Same report last year
    9.3M
    History used
    2,618 days
    2024-02-29: 9.3M2024-03-15: 10.5M2024-03-28: 7.7M2024-04-15: 8.6M2024-04-30: 8.5M2024-05-15: 7.7M2024-05-31: 6.7M2024-06-14: 7.9M2024-06-28: 6.4M2024-07-15: 5.8M2024-07-31: 5.7M2024-08-15: 8.5M2024-08-30: 8.9M2024-09-13: 6.5M2024-09-30: 5.4M2024-10-15: 4.0M2024-10-31: 4.6M2024-11-15: 8.1M2024-11-29: 7.4M2024-12-13: 10.1M2024-12-31: 12.7M2025-01-15: 15.1M2025-01-31: 16.9M2025-02-14: 15.5M2025-02-28: 17.0M
    the 28 Feb 2025 report24 earlier reportsnormal: 8.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 27 Feb 2025Short interest and volume change

    had 15.5M shares sold short in the 14 Feb 2025 report, 1.7× the same report last year.

    Same report last year: 8.9M; its normal report is 8.0M.

    See the evidence
    This period
    15.5M (the 14 Feb 2025 report)
    Normal report (median of 24 earlier)
    8.0M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +3.5
    Same report last year
    8.9M
    History used
    2,604 days
    2024-02-15: 8.9M2024-02-29: 9.3M2024-03-15: 10.5M2024-03-28: 7.7M2024-04-15: 8.6M2024-04-30: 8.5M2024-05-15: 7.7M2024-05-31: 6.7M2024-06-14: 7.9M2024-06-28: 6.4M2024-07-15: 5.8M2024-07-31: 5.7M2024-08-15: 8.5M2024-08-30: 8.9M2024-09-13: 6.5M2024-09-30: 5.4M2024-10-15: 4.0M2024-10-31: 4.6M2024-11-15: 8.1M2024-11-29: 7.4M2024-12-13: 10.1M2024-12-31: 12.7M2025-01-15: 15.1M2025-01-31: 16.9M2025-02-14: 15.5M
    the 14 Feb 2025 report24 earlier reportsnormal: 8.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 14 Feb 2025Institutional holdings record

    Holocene Advisors, LP opened a $282.0M position (2024Q4 13F)

  27. 13 Feb 2025Institutional holdings record

    MARSHALL WACE, LLP opened a $254.0M position (2024Q4 13F)

  28. 12 Feb 2025Short interest and volume change

    had 16.9M shares sold short in the 31 Jan 2025 report, 4.1× the same report last year.

    Same report last year: 4.1M; its normal report is 7.8M.

    See the evidence
    This period
    16.9M (the 31 Jan 2025 report)
    Normal report (median of 24 earlier)
    7.8M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +4.5
    Same report last year
    4.1M
    History used
    2,590 days
    2024-01-31: 4.1M2024-02-15: 8.9M2024-02-29: 9.3M2024-03-15: 10.5M2024-03-28: 7.7M2024-04-15: 8.6M2024-04-30: 8.5M2024-05-15: 7.7M2024-05-31: 6.7M2024-06-14: 7.9M2024-06-28: 6.4M2024-07-15: 5.8M2024-07-31: 5.7M2024-08-15: 8.5M2024-08-30: 8.9M2024-09-13: 6.5M2024-09-30: 5.4M2024-10-15: 4.0M2024-10-31: 4.6M2024-11-15: 8.1M2024-11-29: 7.4M2024-12-13: 10.1M2024-12-31: 12.7M2025-01-15: 15.1M2025-01-31: 16.9M
    the 31 Jan 2025 report24 earlier reportsnormal: 7.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 28 Jan 2025Short interest and volume change

    had 15.1M shares sold short in the 15 Jan 2025 report, 2.6× the same report last year.

    Same report last year: 5.8M; its normal report is 7.7M.

    See the evidence
    This period
    15.1M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    7.7M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +4.0
    Same report last year
    5.8M
    History used
    2,574 days
    2024-01-12: 5.8M2024-01-31: 4.1M2024-02-15: 8.9M2024-02-29: 9.3M2024-03-15: 10.5M2024-03-28: 7.7M2024-04-15: 8.6M2024-04-30: 8.5M2024-05-15: 7.7M2024-05-31: 6.7M2024-06-14: 7.9M2024-06-28: 6.4M2024-07-15: 5.8M2024-07-31: 5.7M2024-08-15: 8.5M2024-08-30: 8.9M2024-09-13: 6.5M2024-09-30: 5.4M2024-10-15: 4.0M2024-10-31: 4.6M2024-11-15: 8.1M2024-11-29: 7.4M2024-12-13: 10.1M2024-12-31: 12.7M2025-01-15: 15.1M
    the 15 Jan 2025 report24 earlier reportsnormal: 7.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 7 May 2024Attention change

    drew 30K Wikipedia page views in the week of 29 Apr 2024, 5.9× the same week last year.

    Same week last year: 5,088; its normal week is 5,736.

    See the evidence
    This period
    30K (the week of 29 Apr 2024)
    Normal week (median of 26 earlier)
    5,736
    Typical spread (median absolute deviation)
    450
    How far from its usual level
    +36.1
    Same week last year
    5,088
    History used
    1,951 days
    2023-10-30: 5,3102023-11-06: 6,4462023-11-13: 5,8772023-11-20: 6,0572023-11-27: 5,6802023-12-04: 5,3442023-12-11: 5,7362023-12-18: 5,0552023-12-25: 4,7022024-01-01: 4,9052024-01-08: 5,6812024-01-15: 5,9062024-01-22: 6,2292024-01-29: 6,1682024-02-05: 6,1242024-02-12: 6,3052024-02-19: 6,9842024-02-26: 6,1752024-03-04: 6,4062024-03-11: 5,7372024-03-18: 6,1982024-03-25: 4,9102024-04-01: 5,2712024-04-08: 5,1962024-04-15: 5,2042024-04-22: 5,4382024-04-29: 30K
    the week of 29 Apr 202426 earlier weeksnormal: 5,736

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  31. 9 Jan 2024Lobbying record

    ASTRAZENECA UK LTD.: lobbying engagement terminated (SQUIRE PATTON BOGGS) (dated 17 Nov 2023)

  32. 9 Nov 2023Institutional holdings record

    Sanders Capital, LLC opened a $715.0M position (2023Q3 13F)

  33. 18 Jul 2023Lobbying record

    ASTRAZENECA PHARMACEUTICALS LP: lobbying engagement terminated (TODD STRATEGY GROUP) (dated 31 Mar 2023)

  34. 19 Jan 2023Lobbying record

    ASTRAZENECA PHARMACEUTICALS LP: lobbying engagement terminated (RAMPY NORTHRUP LLC) (dated 31 Dec 2022)

  35. 18 Jan 2023Lobbying record

    ASTRAZENECA PHARMACEUTICALS LP: lobbying engagement terminated (PRIME POLICY GROUP) (dated 1 Jan 2025)

  36. 6 Jul 2022Lobbying record

    ASTRAZENECA UK LTD.: new lobbying registration (SQUIRE PATTON BOGGS) (dated 23 May 2022)

  37. 25 May 2022Short interest and volume change

    had 16.4M shares sold short in the 13 May 2022 report, 87% below the same report last year.

    Same report last year: 125.4M; its normal report is 7.7M.

    See the evidence
    This period
    16.4M (the 13 May 2022 report)
    Normal report (median of 24 earlier)
    7.7M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +4.3
    Same report last year
    125.4M
    History used
    1,596 days
    2021-04-30: 118.1M2021-05-14: 125.4M2021-05-28: 132.1M2021-06-15: 135.1M2021-06-30: 136.9M2021-07-15: 142.9M2021-07-30: 7.5M2021-08-13: 5.6M2021-08-31: 6.4M2021-09-15: 6.5M2021-09-30: 7.2M2021-10-15: 7.1M2021-10-29: 6.8M2021-11-15: 7.0M2021-11-30: 7.6M2021-12-15: 6.3M2022-01-14: 6.1M2022-01-31: 5.3M2022-02-15: 8.2M2022-02-28: 9.0M2022-03-15: 7.9M2022-03-31: 7.8M2022-04-14: 10.8M2022-04-29: 11.8M2022-05-13: 16.4M
    the 13 May 2022 report24 earlier reportsnormal: 7.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 20 Jan 2022Lobbying record

    BURSON COHN & WOLFE ON BEHALF OF ASTRAZENECA PHARMACEUTICALS LP: lobbying engagement terminated (PRIME POLICY GROUP) (dated 31 Dec 2021)

  39. 20 Jan 2022Lobbying record

    ASTRAZENECA PHARMACEUTICALS LP: new lobbying registration (PRIME POLICY GROUP) (dated 1 Jan 2022)

  40. 15 Nov 2021Institutional holdings change

    saw 163 13F filers open a new position in the quarter ended 30 Sep 2021, 1.5× the same quarter last year.

    Same quarter last year: 106; its normal quarter is 67.5.

    See the evidence
    This period
    163 (the quarter ended 30 Sep 2021)
    Normal quarter (median of 8 earlier)
    67.5
    Typical spread (median absolute deviation)
    14
    How far from its usual level
    +4.6
    Same quarter last year
    106
    History used
    2,922 days
    2019-09-30: 542019-12-31: 622020-03-31: 532020-06-30: 1012020-09-30: 1062020-12-31: 892021-03-31: 542021-06-30: 732021-09-30: 163
    the quarter ended 30 Sep 20218 earlier quartersnormal: 67.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

Showing the newest 40 of 150 entries; narrow the window or the kind of data to see older ones.

Not listed: 12 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000901832
Ticker
AZN
Domain
astrazeneca.com
Hq location
|CAMBRIDGE|CB2 0 (1 unverified)
Lobbying client
astrazeneca, farragut partners on behalf of astra zeneca
Name
AstraZeneca PLC, ZENECA GROUP PLC
Uei
CF9NBBEJ6BY5, G2FBBTMF9F24
Wikidata
Q731938
Wikipedia
AstraZeneca
  • DOL H-1B labor condition applications and PERM certifications53 data points10 Nov 2025 to 31 Aug 2026
  • Federal lobbying disclosures (LDA)73 records, 279 data points26 Mar 1999 to 30 Sep 2026
  • SEC Form 13F institutional holdings26 records, 481 data points30 Jun 2013 to 10 Nov 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)11 records8 Mar 2016 to 24 Feb 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)144 data points31 Dec 2014 to 31 Dec 2025
  • SEC Form 4 insider transactions2 records, 8 data points22 May 2026 to 11 Sep 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards17 records, 1812 data points1 Oct 2007 to 3 Nov 2023
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026